Baird analyst Colleen Kusy raised the firm’s price target on Apellis to $100 from $81 and keeps an Outperform rating on the shares. The firm said following the prior strong 4Q23 pre-announcement, focus was on commentary on 1Q24 and cash guidance and Baird ncreasing its Syfovre estimates in 2024 and beyond.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on APLS:
- Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
- Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
- APLS Earnings this Week: How Will it Perform?
- Apellis Pharmaceuticals to Host Conference Call on February 27, 2024, to Discuss Fourth Quarter and Full Year 2023 Financial Results
- Apellis price target raised to $60 from $49 at Mizuho